论文部分内容阅读
目的探索人用狂犬病疫苗(辽宁成大生物股份有限公司)2-1-1程序能否对狂犬病病毒高危暴露者达到预防效果。方法把29例狂犬病病毒高危暴露者按照原卫生部处置规范分成Ⅱ级暴露组(n=10)、Ⅲ级暴露组(n=19),其中Ⅱ级暴露组按2-1-1程序接种狂犬病疫苗后检测抗狂犬病中和抗体;Ⅲ级暴露组首次接种狂犬病疫苗的同时还接种狂犬病免疫球蛋白;不同组采用狂犬病中和抗体阳转率及平均滴度进行效果分析。结果狂犬病高危暴露者全程使用2-1-1程序后有效得到保护;针对29例狂犬病病毒高危暴露者处置后调查,两组中和抗体阳转率为100%;Ⅲ级暴露组(注射狂犬病免疫球蛋白)与Ⅱ级暴露组(不注射狂犬病免疫球蛋白)中和抗体滴度分别为(7.31±2.03)U/mL和(8.27±2.39)U/mL,两组比较,差异无统计学意义(t=1.16,P>0.05);不同年龄段均产生较相近的阳性滴度,差异无统计学意义(F=1.15,P>0.05);不同性别暴露者产生抗体滴度差异无统计学意义(t=1.19,P>0.05)。结论结合正规的伤口处置,人用狂犬病疫苗2-1-1程序对狂犬病病毒高危暴露者能达到较好的预防效果。
Objective To explore whether the 2-1-1 program for human rabies vaccine (Liaoning Chengda Biotechnology Co., Ltd.) can achieve a preventive effect on high-risk exposure to rabies virus. Methods 29 cases of high risk exposure to rabies virus were divided into grade Ⅱ exposure group (n = 10) and grade Ⅲ exposure group (n = 19) according to the regulations of the former Ministry of Health. The grade Ⅱ exposure group was vaccinated rabies according to 2-1-1 After rabies vaccination, anti-rabies neutralizing antibody was detected. Rabies immunoglobulin was also inoculated simultaneously with the rabies vaccine for the first time in the exposed group and the effect of rabies neutralizing antibody positive rate and average titer in different groups was analyzed. Results The high risk of rabies exposed to 2-1-1 program was effectively protected. After the treatment of 29 rabies virus high-risk exposures, the positive rate of neutralization in the two groups was 100%. The level of exposure to rabies in group Ⅲ (7.31 ± 2.03) U / mL and (8.27 ± 2.39) U / mL respectively, there was no significant difference between the two groups (t = 1.16, P> 0.05). There was no significant difference between the different age groups (F = 1.15, P> 0.05). There was no significant difference in antibody titers (t = 1.19, P> 0.05). Conclusion Combined with the formal wound treatment, rabies vaccine 2-1-1 can effectively prevent rabies virus high-risk exposure.